



APEC on the current effort of Training and Capacity Building initiatives

Muralitharan Paramasua, PhD
Chief Executive of Medical Device Authority (MDA), Malaysia




OVERVIEW

Asia-Pacific Economic Cooperation (APEC)

- Committee on Trade and Investment (CTI)
- 2. Sub-Committee on Standards and Conformance (SCSC)
- 3. Regulatory Harmonization Steering Committee (RHSC) on Medical Products
 - a. Goals, Strategies and Tactics of RHSC

Center of Excellence (CoE) Programs

Summary of CoE Activities (2024 and 2025)



Medical Device Priority Work Areas

- 1. Medical Device PWA Structure
- 2. Key Performance Indicators (KPI) of Medical Device in RHSC
- 3. Medical Device PWA Roadmap
- 4. Medical Device PWA Core Curriculum



Next Steps






APEC 21 Economy Members














Asia-Pacific Economic Cooperation (APEC)



- Established in November 1993
- A forum for APEC's 21 member economies to deliberate on all trade, investment and policy issues
- Guided by the Putrajaya Vision 2040 (PV2040)
- Aligned with Aotearoa Plan of Action, APA (2021), the Bangkok Goals (2022) and the San Francisco Principles (2023)
- 3 times a year (Senior Officials' Meetings)
- Reduce impediments to business activity in the areas outlined by the Osaka Action Agenda 1997 and promote trade and investment as stated in the APA
- Helping APEC economies achieve free and open trade and investment while pursuing the PV2040



CTI GOVERNANCE

APEC Economic Leaders launched the Putrajaya Vision 2040 (PV2040) in 2020 and the Aotearoa Plan of Action (APA) in 2021



Three economic drivers under the PV2040



Trade and Investment;



Innovation and Digitalisation



Strong, Balanced, Secure, Sustainable and Inclusive Growth.

With Peru as the host economy for 2024, the three CTI plenary meetings in 2024 were aligned with the overall CTI work programme



Support the Multilateral Trading System



Aim to deepen
Economic
Integration in
the Region



Promote Trade Facilitation, Connectivity, Digitalisation, and Innovation



Encourage
Inclusion and
Sustainability in
trade practices






2. SCSC UNDER CTI





SCSC's Role in APEC

CTI Oversees 8 Sub-Groups



SCSC Objectives

Reduce Barriers

Focus on minimizing trade obstacles through standards and conformance

Promote GRP

Encourage effective regulatory practices in standards

Regional Cooperation

Promote collaboration in line with global agreements

Education Programs Support awareness initiatives for business capacity building





Align **Standards**

Ensure local standards match international benchmarks



Mutual Recognition

Foster agreements for conformity assessment



Greater **Transparency**

Advocate for openness in standard processes

1st economic driver "Trade and Investment"

- Reducing unnecessary barriers
- Improving economies' transparency through trade measures and policies
- Advance capacity building programmes (WTO Rules) → Transparency & notification obligations
- Promote trade and investment facilitation for all

2nd economic driver "Innovation & Digitalisation"

- Adopt new and emerging technologies
- Address challenges and barriers
- Promote e-commerce / digital trade

3rd economic driver "Strong, Balanced, Secure, Sustainable and Inclusive Growth"

Encourage and exchange best practice policies, and promote capacity building programme





Mutual Objectives

IMDRF

To strategically accelerate international medical device regulatory convergence to promote an efficient and effective regulatory model for medical devices that is responsive to emerging challenges in the sector while protecting and maximizing public health and safety

SCSC

REGULATORY CONVERGENCE



To reduce the negative effects that differing standards and conformance arrangements have on trade and investment flows in the Asia-Pacific Region






3. RHSC UNDER SCSC





SCSC Structure







RHSC GOVERNANCE

In March 2024, CTI endorsed the updated Terms of Reference (ToR) for the SCSC which now incorporates the RHSC as Appendix 5 of SCSC's ToR.

The RHSC's goal is **to promote regulatory convergence** and cooperation for medical products with the objectives of :

- a. facilitating regulatory convergence and cooperation among medical product regulatory authorities;
- building human capacity in regulatory science among medical product regulatory staff; and
- c. promoting convergence and reliance among regulatory policymakers in APEC.





Goals, Strategies & Tactics RHSC





Goal of RHSC: Facilitate regulatory cooperation among medical product regulatory authorities

Strategy: Build alignment

- neutral platforms for cohesion and
- Action: Convene meetings of the RHSC twice per year
- Action: Maintain Priority Work **Areas** (PWAs)
- Action: Create virtual spaces for regulatory cooperation through the RHSC website and email distribution lists

Strategy: Build tools for regulatory information-sharing and work-sharing

- Action: **Development of** template agreements
- Action: **Developing a** technical platform to facilitate information-sharing and work-sharing



Strategy: Promote regulatory convergence and reliance and its tools


- Action: Organize regular workshops to explain and support the use of instruments of reliance
- Action: Support participation in regulatory harmonization
- Action: Explore the feasibility of developing consensus-driven joint APEC commitments and bilateral or multilateral reliance agreements





2

Goal of RHSC: Build human capacity in regulatory science among medical product regulatory staff



- Action: Support the Center of Excellence Coalition
- Action: Encourage consistent, long-term, and peer-to-peer
 Training and the development of peer networks for participants in person and virtually
- Action: Organize ad-hoc virtual and in-person workshops for Center
 Excellence faculty
- Action: **Enable more regulatory staff** from more APEC economies to participate in Center of Excellence training programs by
- Action: Measure the short- and long-term learning outcomes

Strategy: Maintain strategic roadmaps and core curricula to guide programming

 Action: Review roadmaps every 5 years at minimum, and core curricula every 2 years at a minimum



Goal of RHSC: Promote political will for convergence and reliance among regulatory policymakers

Strategy: Explore new ways to measure regulatory convergence and its impacts

- Action: Continue measuring progress towards regulatory convergence with proxy indicators
- Action: Analyze the macroeconomic case for and cost of inaction on regulatory convergence and reliance

Strategy: Support policymakers seeking to establish or change legal frameworks, laws, or regulations


- Action: Organize policy dialogues
- Action: Supply policymakers
 with guiding principles on
 decision-making towards the
 establishment or change of
 legal frameworks, laws, or
 regulations, when needed

Strategy: Elevate the case for regulatory convergence and reliance, including at the highest political levels

- Action: Issue an annual letter from the RHSC
 Co-Chairs to the heads of RA
- Action: Organize policy dialogues to discuss regulatory convergence and reliance
- Action: Secure continued high-level political support
- Action: Position APEC economies as champions of regulatory convergence and share progress with non-APEC economies












5. MEDICAL DEVICE PWA UNDER RHSC





MEDICAL DEVICE PWA STRUCTURE








KPI in RHSC for Medical Devices

Establishment and monitoring of **eight (8) key performance indicators (KPIs)** to measure progress towards achieving **regulatory convergence for medical devices** over the last decade and on an annual basis, including:







RHSC MD PWA ROADMAP (endorsed on 26/2/25)




International harmonization initiatives

Promotes global standards for MD



Regulatory Capacity Building

Enhances regulatory knowledge and skills



Harmonized Implementation Support

Facilitates consistent application across economies


Regulatory Convergence

Promotes regulatory convergence for medical device regulatory system



MD PWA CURRICULUM

NUMBER OF IMDRF DOCUMENT USED IN COE PROGRAM







EXAMPLE OF MD PWA CURRICULUM

Category	Elements	GHTF/IMDRF Documents and Standards
Pre-market	Medical Device Definitions	Definition of the Terms 'Medical Device' and 'In Vitro Diagnostic (IVD) Medical Device' (SG1/N071: 2012) http://www.imdrf.org/docs/ghtf/final/sg1/technical-docs/ghtf-sg1-n071-2012-definition-of-terms-120516.pdf
Pre-market	Medical Device Definitions	Definitions of the Terms Manufacturer, Authorised Representative, Distributor and Importer (SG1/N055: 2009) http://www.imdrf.org/docs/ghtf/final/sg1/technical-docs/ghtf-sg1-n055-definition-terms-090326.pdf
Pre-market	Medical Device Classification	Principles of Medical Device Classification (SG1/N77: 2012) http://www.imdrf.org/docs/ghtf/final/sg1/technical-docs/ghtf-sg1-n77-2012-principles-medical-devices-classification-121102.pdf
Pre-market	Medical Device Classification	Principles of In Vitro Diagnostic (IVD) Medical Devices Classification (IMDRF/IVD WG/N64FINAL:2021 (formerly GHTF/SG1/N045:2008)) http://www.imdrf.org/docs/imdrf/final/technical/imdrf-tech-wng64.pdf





EXAMPLE OF MD PWA CURRICULUM

Category	Elements	GHTF/IMDRF Documents and Standards	
QMS	Quality Management Systems and Risk Management	ISO13485: 2016 Medical devices Quality management systems Requirements for Regulatory Purposes	
QMS	Quality Management Systems and Risk Management	ISO 14971: 2019 Medical Devices - Application of Risk Management for Medical Devices	
Postmarket Adverse Event Reporting		Medical Devices Post Market Surveillance: Global Guidance for Adverse Event Reporting for Medical Devices (GHTF/SG2/N54R8:2006) http://www.imdrf.org/docs/ghtf/final/sg2/technical-docs/ghtf-sg2-n54r8 guidance-adverse-events-061130.pdf IMDRF terminologies for categorized Adverse Event Reporting (AER) terms, terminology structure and codes (Edition 4) (IMDRF/AE WG/N43FINAL:2020) http://www.imdrf.org/docs/imdrf/final/technical/imdrf-tech-200318-ae-terminologies-n43.pdf IMDRF/AE WG/N43FINAL: Updated Annexes https://www.imdrf.org/documents/terminologies-categorized-adverse-event-reporting-aer-terms-terminology-and-codes	





Summary of CoE Activities (2024 and 2025)

Name of institution	Economy	2024	2025 (Plan)
Sichuan University (SCU)	China	✓	
Pharmaceuticals and Medical Devices Agency (PMDA)	Japan	✓	-
Soonchunhyang University (SCH)	Korea	✓	✓
Taiwan Food and Drug Administration (TFDA)	Chinese Taipei	✓	✓
University of Southern California (USC)	United States	✓	√

Malaysia MDA nominates to become Pilot CoE



1) Soon Chun Hyang University (SCH) APEC Medical Device

CoE, Rep. of Korea

Application

- Application for candidate CoE and CoE pilot training
- RHSC endorsed SCH pilot application (Jun 2020)

Formal CoE

- Conducted a CoE pilot training (Oct Nov 2020)
- Recognition as a formal CoE (Dec 2020)

CoE Training

- 2021 SCH APEC MD CoE Training (Sep 2021)
- 2022 SCH APEC MD CoE Training (Nov 2022)
- 2023 SCH APEC MD CoE Training (Nov 2023)
- 2024 SCH APEC MD CoE Training (Oct 2024)



APEC LIFE SCIENCES INNOVATION FORUM REGULATORY HARMONIZATION STEERING COMMIT



16 December 2020

Prof You Kyoung Lee
Director of SCH Medical Device TPLC Regulatory Science Research Center (MDRS)
Soonchunhyang University
170 Jomaru-ro, Bucheon-si, Gyeonagi-do, 14584 Republic of Korea

Dear Prof You Kyoung Lee,

Thank you for your application to formalize your institution as an APEC LSIF Training Center of Excellence for Regulatory Science (CoE) for *Medical Devices* on 3 December 2020. On behalf of the APEC Regulatory Harmonization Steering Committee (RHSC), we are pleased to notify you of RHSC's endorsement of this opportunity.

Included with this endorsement is the CoE reference document package that describes the *Operating Model and Guidelines* outlines expectations of both parties, as well as a *Memorandum of Understanding* (MoU) between your institution and APEC's Life Sciences Innovation Forum (LSIF) within which RHSC operates. Please complete this MoU and send a signed copy to the RHSC Co-Chairs within 30 days for approval and signature by the LSIF Planning Group Chair.

Should you have any questions, please feel free to contact the PWA CoE Program Committee or the RHSC Co-Chairs for assistance.

Thank you for your participation in this exciting initiative.

Sincerely,

Michelle Landi

Dr Michelle Limoli Co-Chair APEC RHSC



Dr Nobumasa Nakashima Co-Chair APEC RHSC

2024 SCH APEC Medical Device CoE Training Survey result



Participants and Participating Economies


(2020) 10 economies, 130 Participants

(2021) 13 economies, 138 participants

(2022) 18 economies, 129 participants

(2023) 16 economies, 115 participants

(2024) 25 economies, 232 participants





Satisfaction Survey


Overall satisfaction 4.64


Training topics satisfaction 4.62



2024 SCH APEC Medical Device CoE Training Trainees' data analysis












2024 SCH APEC Medical Device CoE Training Trainees' data analysis

Participants by Sector



Regulator – 165 participants (71.1%)

Academia – 23 participants (9.9%)

Industry – 15 participants (6.5%)

Health Care Provider- 15 participants (6.5%)

ETC (International Organization, consulting company, INGO, etc.) – 14 participants (6%)

2) USC Mann DK Kim International Center for Regulator Science



Top-Line Summary

Registrations:

16 registered

7 canceled

9 on-site from 5 economies,

Speakers: 12

Areas of interest for participants:

- Case Studies of Design Control
- Risk Management
- Conformity Assessments
- Outcomes





Attendee Demographics (n=9)

- · 1 Chile
- 2 Indonesia
- 2 Malaysia
- 2 Papua New
 Guinea
- 2 Peru

Institution	Number of Attendees	
Medical Device Authority, Ministry of Health, Malaysia	1	
Medical Device Authority, Malaysia	1	
National Department of Health Papua New Guinea	2	
General Directorate of Medicines Supplies and Drug, Peru	2	
Ministry of Health, Republic of Indonesia	2	
Instituto de Salud Pública de Chile	1	
	The second second second second second	





3) PMDA-ATC

CoE Update: Medical Device PWA

KANEMATSU Miwa

Pharmaceuticals and Medical Devices Agency (PMDA)

Japan







Participants

Participants: 37 from 22 economies

APEC Economi	es	No	n-APEC Economies		
Australia	4	Algeria	2	Nepal	1
Brunei Darussalam	2	Bangladesh	1	Pakistan	2
Chinese Taipei	1	Egypt	1	South Africa	2
The Philippines	1	El Salvador	2	Sri Lanka	2
Singapore	1	Ethiopia	2	Tanzania	1
Thailand	2	Guyana	1	Timor-Leste	1
		India	2	Uganda	1
		Myanmar	2	Uzbekistan	3





Program

Day 1: Lectures on the international harmonization of medical device regulations, reviews of medical devices and QMS for medical devices

Day 2: A case study on the post-market safety measures for medical devices

PMDA lecturers



Participants







Satisfaction of Participants

Comments from the participants



In general, the webinar is useful to know the area that we are not very aware of such as IMDRF terminology.

It is a great opportunity for us to learn developed regulatory system to apply this knowledge in the development of their own regulation.

A wonderful opportunity.

I got to learn a lot of things
I can implement in my economy.







What to expect

- Enhance the cooperation between IMDRF and APEC; usage of document, expand the scope of the curriculum in the capacity building program (eg; regulatory sandbox, agile regulatory governance, digitalisation)
- Promote regulatory convergence among APEC economies to facilitate the trade
- Mutual cooperation to address the issue of tariff and nontariff (technical regulation)





Thank you/Questions

Text style

- Bullet level 1 style
- Bullet level 2 style
 - Bullet level 3 style

Subhead style